Biotech companies directory 2026

    Biotech Companies in India

    India is the volume biologics manufacturing country that Gulf and African tenders already meet as a pack: Serum Institute still makes more vaccines than any other private plant on earth, Biocon and Dr. Reddy’s sell biosimilars into regulated markets, and a Hyderabad–Bengaluru–Pune triangle of CDMOs and vaccine halls sits under CDSCO rather than under a Gulf localisation ministry.

    Bharat Biotech, Biological E, Zydus Lifesciences, Panacea Biotec, Gennova and Intas add further antigen, mRNA, plasma and monoclonal capacity. Syngene, the Biocon group’s listed research-services arm, is the discovery and development CDMO that Western sponsors already have on a framework. MedGenome and Strand Life Sciences sit on the genomics and diagnostics side. The Department of Biotechnology and BIRAC fund and incubate; CDSCO’s Central Drugs Standard Control Organisation registers biologicals and inspects plants. This is not a Doha genome-programme map and it is not a Riyadh PIF joint-venture map. BioNixus groups manufacturers, CDMOs, genomics houses and the two public desks so a licensing, biosimilar-partner or vaccine-tender brief names the hall, the CDSCO file and the export market — not “Indian biotech” as a mood.

    Updated September 2026 · Central Drugs Standard Control Organisation (CDSCO) — biologicals, vaccines and rDNA product registration as of September 2026 · 18 named accounts

    Request a proposal for IndiaBrowse the 18 companies

    SII

    Serum Institute of India — the private vaccine manufacturer most UN and African tenders already know

    3

    Cities that dominate industry plant tours: Pune, Bengaluru and Hyderabad (with Ahmedabad for Zydus)

    BIRAC

    Biotechnology Industry Research Assistance Council — the grant and incubation desk under DBT

    CDSCO

    National biologicals registrar and GMP inspector for vaccines, biosimilars and rDNA products

    Named accounts

    Top biotechnology companies in India

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Central Drugs Standard Control Organisation (CDSCO) — biologicals, vaccines and rDNA product registration (as of 2026-09-05).
    #CompanyHQ
    01Serum Institute of IndiaPune
    02Biocon BiologicsBengaluru
    03Syngene InternationalBengaluru
    04Bharat BiotechHyderabad
    05Biological EHyderabad
    06Dr. Reddy's Laboratories — biologicsHyderabad
    07Zydus Lifesciences — biologics and vaccinesAhmedabad
    08Panacea BiotecNew Delhi
    09Gennova BiopharmaceuticalsPune
    10Intas Pharmaceuticals — biologicsAhmedabad
    11Reliance Life SciencesNavi Mumbai
    12MedGenomeBengaluru
    13Strand Life SciencesBengaluru
    14Bharat Serums and VaccinesMumbai
    15Central Drugs Standard Control Organisation (CDSCO) — biologicalsNew Delhi
    16Biotechnology Industry Research Assistance Council (BIRAC)New Delhi
    17Department of Biotechnology (DBT)New Delhi
    18National Pharmaceutical Pricing Authority (NPPA)New Delhi

    Primary research

    These are the biotech and innovation accounts we track in India

    Partnering, licensing or launching a biologic in India? BioNixus runs KOL, payer and regulator interviews plus hospital-level demand sizing. Proposal within 48 hours.

    Planning research in India?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in India (2026)

    How the market is structured

    How CDSCO files, BIRAC grants and export halls move Indian biologics

    A vaccine or biosimilar that will be sold in India needs a CDSCO biologicals licence, a manufacturing site that inspectors have seen, and usually a price conversation with the National Pharmaceutical Pricing Authority or with state tenders. A vaccine that will be sold to UNICEF, Gavi or African ministries still needs that Indian licence as the home-file, then WHO prequalification and a filling line that can hit the tender’s presentation. Serum Institute in Pune, Bharat Biotech in Hyderabad, Biological E and Panacea run that export machine; Biocon Biologics, Dr. Reddy’s biosimilars, Zydus and Intas run the monoclonal and insulin-analogue machine that aims at EMA, MHRA, ANVISA and increasingly at FDA. Syngene sells capacity rather than a finished brand. BIRAC and DBT grants matter for start-ups and for specific antigen or cell-and-gene programmes; they do not replace a CDSCO file. Hospital demand inside India is a mix of CGHS and state tenders, large private chains (Apollo, Fortis, Narayana, Manipal) and a cash pharmacy market that will substitute a biosimilar when the originator price is theatrical. Cold chain from Pune or Genome Valley to a Nairobi or Jakarta airport is a logistics product, not a footnote. Feasibility that quotes “India’s 1.4 billion people” without naming a plant, a CDSCO division and an export versus domestic split will mis-brief both a Gulf offtake deal and a Western CDMO dual-source.

    Local

    Pune, Hyderabad, Bengaluru and Ahmedabad manufacturers — Serum, Bharat Biotech, Biological E, Biocon Biologics, Zydus, Intas, Gennova, Panacea — that actually fill and export.

    • Serum Institute of India
    • Biocon Biologics
    • Syngene International
    • Bharat Biotech
    • Biological E
    • Dr. Reddy's Laboratories — biologics
    • Zydus Lifesciences — biologics and vaccines
    • Panacea Biotec
    • Gennova Biopharmaceuticals
    • Intas Pharmaceuticals — biologics
    • Reliance Life Sciences
    • MedGenome
    • Strand Life Sciences
    • Bharat Serums and Vaccines

    Multinational

    Originator affiliates and Western sponsors that dual-source from Indian CDMOs or that compete with Indian biosimilars in hospital tenders; they are not the industrial centre of gravity here.

    Regional

    Indian groups themselves are the regional suppliers into Africa, ASEAN and the Middle East; incoming Gulf plants are buyers of these packs, not tenants of Genome Valley.

    Incubators, CDMOs & partners

    CDSCO biologicals division, BIRAC and DBT, NPPA pricing, and the UN/Gavi and state-tender desks that turn a licensed vial into volume.

    • Central Drugs Standard Control Organisation (CDSCO) — biologicals
    • Biotechnology Industry Research Assistance Council (BIRAC)
    • Department of Biotechnology (DBT)
    • National Pharmaceutical Pricing Authority (NPPA)

    What is moving

    What is moving biotechnology in India

    WHO prequalification as an export gate

    UNICEF and Gavi volumes still require a prequalified presentation and a filling line that can hit the award; Serum, Bharat Biotech and Biological E live on that clock.

    Biosimilars into regulated markets

    Biocon Biologics, Dr. Reddy’s, Zydus and Intas are building EMA and FDA files that change how a European hospital pharmacist sees an “Indian biologic.”

    CDMO dual-source demand

    Syngene and peer development shops pick up Western programmes that want a second geography without a Gulf-style joint-venture offtake.

    Domestic hospital and tender substitution

    Apollo, state tenders and CGHS will switch to a licensed biosimilar when the originator price is indefensible, which is why a India brief must split export halls from domestic field forces.

    BioNixus fieldwork

    How BioNixus studies biotechnology companies in India

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in India:
    • Hospital-pharmacist interviews in Mumbai, Delhi-NCR, Hyderabad and Bengaluru on insulin and monoclonal biosimilar switching versus originators.
    • Plant-capability discussions in Pune, Genome Valley and Bengaluru that record inspected lines versus announced expansions.
    • Tender-award mapping for state and CGHS biologicals versus UNICEF/Gavi export presentations.
    • CDSCO and BIRAC pathway walkthroughs with inbound licensing teams that still treat India as a Gulf-style joint-venture market.

    Healthcare market research in India

    Questions

    Frequently Asked Questions

    Which Indian companies actually manufacture vaccines at global scale?

    Serum Institute of India first, then Bharat Biotech, Biological E, Panacea Biotec and Zydus on selected antigens. Gennova is the mRNA specialist. Do not collapse them into one “Pune cluster.”

    Who leads Indian biosimilars?

    Biocon Biologics is the name Western inspectors already know. Dr. Reddy’s, Zydus, Intas and Reliance Life Sciences add further monoclonal, insulin and plasma files.

    What does CDSCO require for a biological?

    A biologicals licence, inspected manufacturing, and — for rDNA products — additional rDNA and sometimes GEAC overlays. BIRAC funding is not a substitute for that file.

    Where should a plant tour go?

    Pune for Serum and Gennova, Genome Valley / Hyderabad for Bharat Biotech, Biological E and Dr. Reddy’s, Bengaluru for Biocon and Syngene, Ahmedabad for Zydus and Intas.

    What fieldwork does BioNixus run on Indian biotechnology organisations?

    Hospital-pharmacist and tender interviews on biosimilar switching in Mumbai, Delhi, Hyderabad and Bengaluru; plant-capability discussions that separate licensed lines from announced capacity; and CDSCO/BIRAC pathway mapping for inbound partners.

    Does table order rank Indian biotech companies by revenue?

    It does not. Entries are here because they recur in BioNixus India hospital, tender and partnering work and on CDSCO biologicals records. The sort is by role: vaccine hall, biosimilar house, CDMO, genomics, public desk.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in India. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Central Drugs Standard Control Organisation (CDSCO) — biologicals, vaccines and rDNA product registration, consulted 2026-09-05. Company classification (Local / MNC / Regional / incubators, cdmos & partners) reflects ownership and role in India, not size.

    • CDSCO biologicals and vaccine establishment materials
    • Company disclosures of Serum Institute, Biocon Biologics, Syngene, Bharat Biotech, Biological E, Dr. Reddy’s, Zydus Lifesciences and Intas
    • Department of Biotechnology and BIRAC public programme descriptions; NPPA schedule materials where biologicals are listed
    • BioNixus India biologics, vaccine-tender and hospital-pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need biotech and biologics market data in India?

    Payer appetite, biosimilar uptake, KOL sentiment and tender exposure — primary research, not desk estimates.

    Planning research in India?

    Primary research, market access & HEOR. Proposals within 48 hours.